Real-World Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry

SGLT2i use over time, by subgroup

With vs without T2DM

from 46.2% and 12.5% to 69.8% and 55.4%

eGFR <60 vs ≥60 ml/min/1.73 m²

from 14.7% and 22.3% to 58.0% and 59.8%

Males vs females

from 21.0% and 18.9% to 61.6% and 52.0%

With vs without recent HF hospitalization

from 24.2% and 18.0% to 60.8% and 57.7%

Inpatients vs outpatients

from 26.1% and 19.8% to 54.7% and 59.6%

HF duration <6 vs ≥6 months

from 20.2% and 21.2% to 59.2% and 58.7%

Characteristics associated with SGLT2i use (multivariable logistic regression)

More use: male sex, recent HF hospitalization, specialized HF follow-up, lower EF, T2DM, higher education level, use of other HF/CV interventions

Less use: older age, higher BP, AF, anaemia

Discontinuation of SGLT2i · 6 and 12 months

Discontinuation at 6 months

13.1%

Discontinuation at 12 months

20.0%